Trial Profile
Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Acute heart failure; Myocardial reperfusion injury; Pulmonary hypertension
- Focus Therapeutic Use
- 24 Dec 2021 Primary endpoint has not been met. (BNP levels)
- 24 Dec 2021 Primary endpoint has not been met. (Troponin level)
- 24 Dec 2020 Results published in the Drugs in R and D